Analysts’ Opinions Are Mixed on These Healthcare Stocks: Valeant Pharma (NYSE: VRX) and Align Tech (NASDAQ: ALGN)

By Carrie Williams

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Valeant Pharma (NYSE: VRX) and Align Tech (NASDAQ: ALGN).

Valeant Pharma (NYSE: VRX)

In a report released today, Gregg Gilbert from Deutsche Bank maintained a Hold rating on Valeant Pharma (NYSE: VRX), with a price target of $19. The company’s shares opened today at $17.31.

According to TipRanks.com, Gilbert is a 1-star analyst with an average return of -1.8% and a 45.0% success rate. Gilbert covers the Healthcare sector, focusing on stocks such as Amag Pharmaceuticals, Jazz Pharmaceuticals, and Endo International.

Valeant Pharma has an analyst consensus of Hold, with a price target consensus of $18.

Align Tech (NASDAQ: ALGN)

Morgan Stanley analyst Steve Beuchaw maintained a Buy rating on Align Tech (NASDAQ: ALGN) today and set a price target of $182. The company’s shares opened today at $155.01, close to its 52-week high of $156.98.

According to TipRanks.com, Beuchaw is a 4-star analyst with an average return of 14.8% and a 63.4% success rate. Beuchaw covers the Healthcare sector, focusing on stocks such as Varian Medical Systems, DENTSPLY SIRONA Inc, and Myriad Genetics.

Currently, the analyst consensus on Align Tech is Strong Buy and the average price target is $162.40, representing a 4.8% upside.

In a report issued on July 4, Jefferies also reiterated a Buy rating on the stock with a $150 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.